S

Septerna

Biotech & Life Sciences · San Francisco, United States · Founded 2022 · IPO 2024

Septerna is a pioneering startup in the biotechnology sector, focusing on the development of G protein-coupled receptors (GPCRs) drug discovery. GPCRs are proteins that play a crucial role in regulating human physiology and are a significant target for pharmaceuticals. However, many potential GPCR targets have been inaccessible to modern drug discovery technologies. Septerna is changing this scenario with its innovative Native Complex™ Platform. The Native Complex™ Platform is a groundbreaking technology that reproduces GPCRs with their original structure, function, and dynamics outside of the cellular environment. This technology allows for the first time, the industrial-scale drug discovery, including structure-based drug design and ultra-large-scale screening for the entire GPCR target class. This opens up new opportunities for previously "undruggable" GPCRs to be used as therapeutic targets. Septerna's business model is centered around the development and commercialization of this platform. The company's primary clients are likely to be pharmaceutical companies seeking to develop new drugs targeting GPCRs. By offering a solution to a previously unmet need in the pharmaceutical industry, Septerna has positioned itself in a niche market with significant potential for growth. Septerna generates revenue by licensing its technology to pharmaceutical companies for drug discovery and development. The company also stands to earn from the sale of its proprietary GPCR-targeted medicines. In summary, Septerna is a game-changer in the biotech industry, leveraging its innovative technology to unlock new therapeutic targets and spearhead a new era of GPCR-targeted medicines. Keywords: Biotechnology, G protein-coupled receptors (GPCRs), Drug Discovery, Native Complex™ Platform, Pharmaceutical Industry, Therapeutic Targets, Structure-Based Drug Design, Large-Scale Screening, GPCR-Targeted Medicines, Licensing.